181021-20-5

Basic information

• Product Name: 2-(2-tert-Butyldimethylsilyloxyethyl)bromobenzene
• Synonyms: (2-Bromophenethoxy)(tert-butyl)dimethylsilane;2-(2-tert-Butyldimethylsilyloxyethyl)bromobenzene;2-(2-tert-Butyldimethylsilyloxyethyl)bromobenzene 98%;(2-Bromophenethoxy)(t-butyl)dimethylsilane;2-(2-t-butyldimethylsilyloxyethyl)bromobenzene;2-(2-tert-Butyldimethylsilyloxyethyl)bromobenzene98%
• CAS NO: 181021-20-5
• Molecular Formula: C₁₄H₂₃BrOSi
• Molecular Weight: 315.32132
• Product Categories: blocks;Bromides
• Mol File: 181021-20-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 314.9°Cat760mmHg
• Flash Point: 144.3°C
• Appearance: /
• Density: 1.127g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.496
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(2-tert-Butyldimethylsilyloxyethyl)bromobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-tert-Butyldimethylsilyloxyethyl)bromobenzene(181021-20-5)
• EPA Substance Registry System: 2-(2-tert-Butyldimethylsilyloxyethyl)bromobenzene(181021-20-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 181021-20-5(Hazardous Substances Data)

Usage

General Description

2-(2-tert-Butyldimethylsilyloxyethyl)bromobenzene is a chemical compound that consists of a benzene ring with a bromine atom and a 2-(2-tert-Butyldimethylsilyloxyethyl) group attached to it. The 2-(2-tert-Butyldimethylsilyloxyethyl) group contains a silicon atom bonded to two methyl groups and a tert-butyl group, as well as an oxygen atom bonded to an ethyl group. 2-(2-tert-Butyldimethylsilyloxyethyl)bromobenzene is commonly used in organic synthesis as a building block for the preparation of various organic molecules. It can undergo various chemical reactions such as substitution, addition, and elimination to generate new compounds with different properties and functionalities. Due to its reactivity and versatility, 2-(2-tert-Butyldimethylsilyloxyethyl)bromobenzene is an important intermediate in the production of pharmaceuticals, agrochemicals, and materials.

InChI:InChI=1/C14H23BrOSi/c1-14(2,3)17(4,5)16-11-10-12-8-6-7-9-13(12)15/h6-9H,10-11H2,1-5H3

Upstream product

• 18698-97-0 ortho-bromophenylacetic acid 
• 1074-16-4 2-bromophenylethyl alcohol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 81168-10-7 2-<2-(t-Butyldimethylsilyloxy)ethyl>benzaldehyde 
• 1402599-29-4 C₃₂H₃₉NO₆SSi 
• 1056990-63-6 8-[2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)phenyl]-1,4-dioxaspiro[4.5]decan-8-ol 
• 181021-23-8 C₂₇H₃₅NO₆S 
• 181021-21-6 tert-Butyl-(2-{2-[1-(2,2-dimethoxy-ethyl)-prop-2-ynyl]-phenyl}-ethoxy)-dimethyl-silane 
• 181021-22-7 2-{2-[1-(2,2-Dimethoxy-ethyl)-prop-2-ynyl]-phenyl}-ethanol 
• 517883-73-7 2-{2-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-phenyl}-pyridine 
• 224184-32-1 1-<4-(2-chloroethoxy)phenyl>-1-<2-(O-(tert-butyldimethylsilyl)ethyl)phenyl>-2-phenyl butan-1-ol 
• 181020-99-5 tert-Butyl-dimethyl-[2-(2-prop-2-ynyl-phenyl)-ethoxy]-silane 

Relevant articles and documents

Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer

SUMOylation is a reversible post-translational modification that regulates protein function through covalent attachment of small ubiquitin-like modifier (SUMO) proteins. The process of SUMOylating proteins involves an enzymatic cascade, the first step of which entails the activation of a SUMO protein through an ATP-dependent process catalyzed by SUMO-activating enzyme (SAE). Here, we describe the identification of TAK-981, a mechanism-based inhibitor of SAE which forms a SUMO-TAK-981 adduct as the inhibitory species within the enzyme catalytic site. Optimization of selectivity against related enzymes as well as enhancement of mean residence time of the adduct were critical to the identification of compounds with potent cellular pathway inhibition and ultimately a prolonged pharmacodynamic effect and efficacy in preclinical tumor models, culminating in the identification of the clinical molecule TAK-981.

Spirocyclic tetrahydroquinazolines

The invention discloses spirocyclic tetrahydroquinazolines , and particularly provide compounds represented by Formula I shown in the specification, and pharmaceutically acceptable salts and solvates thereof. In the formula, R3, A, A1, A2, A3, E, E1, E2, L, Q, Z and a structure shown in the specification are as defined in the specification,. The compounds of formula I are KRAS inhibitors and are therefore useful in the treatment of cancer and other diseases.

2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation

Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.